Veterinary and comparative oncology最新文献_第7页

Pilot study to evaluate isolation by size of circulating tumour cells in canine oral melanoma. 评估犬口腔黑色素瘤循环肿瘤细胞大小分离的试点研究。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2024-09-01 Epub Date: 2024-06-04 DOI: 10.1111/vco.12982

Victor Nowosh, Alexcia Camila Braun, Anna Paula Carreta Ruano, Ludmilla Thomé Domingos Chinén, Cristina de Oliveira Massoco

{"title":"Pilot study to evaluate isolation by size of circulating tumour cells in canine oral melanoma.","authors":"Victor Nowosh, Alexcia Camila Braun, Anna Paula Carreta Ruano, Ludmilla Thomé Domingos Chinén, Cristina de Oliveira Massoco","doi":"10.1111/vco.12982","DOIUrl":"10.1111/vco.12982","url":null,"abstract":"Liquid biopsy for circulating tumour cell (CTC) detection is generally unexplored in veterinary medicine. Dogs with highly aggressive and heterogeneous tumours, such as oral malignant melanoma (OMM), could benefit from studies involving size-based isolation methods for CTCs, as they do not depend on specific antibodies. This pilot study aimed to detect CTCs from canine OMM using Isolation by Size of Epithelial Tumor Cells (ISET), a microfiltration methodology, followed by immunocytochemistry (ICC) with Melan-A, PNL2, and S100 antibodies. Ten canine patients diagnosed by histopathology and confirmed as OMM by immunohistochemistry were enrolled, their prognostic data was assessed, and blood samples were collected for CTC analysis. Results have shown the detection of intact cells in 9/10 patients. ICC has shown 3/9 Melan-A-positive, 3/9 PNL2-positive, and 8/9 S100-positive patients, confirming the importance of opting for a multimarker assay. A significant number of negative-stained CTCs were found, suggesting their high heterogeneity in circulation. Microemboli stained with either PNL2 or S100 were found in a patient with a high isolated cell count and advanced clinical stage. Preliminary statistical analysis shows a significant difference in CTC count between patients with and without lymph node metastasis (p < .05), which may correlate with tumour metastatic potential. However, we recommend further studies with more extensive sampling to confirm this result. This pilot study is the first report of intact CTC detection in canine OMM and the first application of ISET in veterinary medicine, opening new possibilities for liquid biopsy studies in canine OMM and other tumours.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"388-397"},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141262974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population Pharmacokinetics, Pharmacodynamics and Safety Properties of Trametinib in Dogs With Cancer: A Phase I Dose Escalating Clinical Trial. 癌症犬服用曲美替尼的群体药代动力学、药效学和安全性特性：I 期剂量递增临床试验。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2024-09-01 Epub Date: 2024-06-18 DOI: 10.1111/vco.12989

Marilia Takada, Keita Kitagawa, Yongzhen Zhang, Jürgen B Bulitta, Steven Moirano, Abigail Jones, Jennifer Borgen, Ashley Onsager, Tuddow Thaiwong, David M Vail

{"title":"Population Pharmacokinetics, Pharmacodynamics and Safety Properties of Trametinib in Dogs With Cancer: A Phase I Dose Escalating Clinical Trial.","authors":"Marilia Takada, Keita Kitagawa, Yongzhen Zhang, Jürgen B Bulitta, Steven Moirano, Abigail Jones, Jennifer Borgen, Ashley Onsager, Tuddow Thaiwong, David M Vail","doi":"10.1111/vco.12989","DOIUrl":"10.1111/vco.12989","url":null,"abstract":"MAPK has been reported as a key oncogenic pathway for canine histiocytic sarcoma, which can be pharmacologically targeted with trametinib, a small inhibitor of MEK1/2. Preliminary data showed promising antitumor activity in in vitro and in vivo models and represented a proof of concept to translate the findings from bench to bedside. In this phase I, dose escalating study using a 3 + 3 cohort design, trametinib was evaluated in 18 dogs with cancer. Adverse events were graded according to VCOG-CTCAE v2. Blood samples and tumour biopsies were collected for pharmacokinetic and pharmacodynamic assessment. Trametinib was well tolerated with a maximum tolerated dose of 0.5 mg/m2/day, PO. Dose-limiting toxicities included systemic hypertension, proteinuria, lethargy and elevated ALP, and were all Grade 3. The drug exposures increased more than linearly with dose since the elimination of trametinib was saturable. At a dose of 500 μg Q24h (0.5 mg/m2/day in a 30 kg dog), approximately 70% of dogs had an average steady-state concentration of 10 ng/mL, achieved after approximately 2 weeks. This threshold was associated with clinical efficacy in humans. Target engagement was not observed in biospecimens collected on Days 0 and 7. In conclusion, trametinib was considered safe in dogs with cancer, and the dose of 0.5 mg/m2/day was the recommended dose for phase II studies.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"410-421"},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas. 一个健康：针对人类和犬组织细胞肉瘤和树突状细胞肉瘤基因变异的疗法。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2024-09-01 Epub Date: 2024-06-12 DOI: 10.1111/vco.12988

Suzanne Agnes Erich, Erik Teske

{"title":"One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas.","authors":"Suzanne Agnes Erich, Erik Teske","doi":"10.1111/vco.12988","DOIUrl":"10.1111/vco.12988","url":null,"abstract":"The precise cause of HS/DCS is still unknown. The relatively low incidence in humans urges for an animal model with a high incidence to accelerate knowledge about genetics and optimal treatment of HS/DCS. Namely, until now, the therapies targeting genetic variants are still more experimental and sparsely used, while consensus is missing. In addition, the literature about variants and possible mutation-targeted therapies in humans and dogs consists mainly of case reports scattered throughout the literature. Therefore, an overview is provided of all currently known genetic variants in humans and dogs with HS/DCS and its subtypes, their possible mutation-targeted therapies, their efficacy, and a contemplation about the future. Several genetic variants have already been discovered in HS/DCS, of which many are shared between canine and human HS/DCS, but unique variants exist as well. Unfortunately, none of these already found variants seem to be specifically causal for HS/DCS, and the puzzle of its landscape of genetic variation is far from complete. The use of mutation-targeted therapies, including MAPK-/MEK-inhibitors and the future use of PTPN11-, CDK4/6- and PD-1-inhibitors, seems to be promising for these specific variants, but clearly, clinical trials are needed to determine optimal inhibitors and standardised protocols for all variants. It can be concluded that molecular analysis for variants and subsequent mutation-targeted therapy are an essential addition to cancer diagnostics and therapy. A joint effort of humans and dogs in research is urgently needed and will undoubtedly increase knowledge and survival of this devastating disease in dogs and humans.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"322-339"},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Electrochemotherapy in dogs and cats-A review. 猫狗的电化学疗法--综述。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2024-09-01 Epub Date: 2024-06-12 DOI: 10.1111/vco.12980

Sofia Chichorro Ramos, Patrícia Dias-Pereira, Ana Lúcia Luís, Michael MacFarlane, Andreia Alexandra Santos

引用次数: 0

Comparison of Three Chemotherapy Protocols With Electrochemotherapy for the Treatment of Feline Cutaneous Squamous Cell Carcinoma. 比较三种化疗方案与电化学疗法治疗猫皮肤鳞状细胞癌的效果

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2024-09-01 Epub Date: 2024-07-15 DOI: 10.1111/vco.12995

Nicolas Diop, David Sayag, Grégoire Bernardo Marques, Gabriel Chamel, Thomas Chavalle, Jean-Bapiste Eon, Franck Floch, Mathilde Lajoinie, Frédérique Ponce, Laura E Barrett

{"title":"Comparison of Three Chemotherapy Protocols With Electrochemotherapy for the Treatment of Feline Cutaneous Squamous Cell Carcinoma.","authors":"Nicolas Diop, David Sayag, Grégoire Bernardo Marques, Gabriel Chamel, Thomas Chavalle, Jean-Bapiste Eon, Franck Floch, Mathilde Lajoinie, Frédérique Ponce, Laura E Barrett","doi":"10.1111/vco.12995","DOIUrl":"10.1111/vco.12995","url":null,"abstract":"Electrochemotherapy (ECT) with intravenous (IV) and/or intratumoral (IT) bleomycin has shown considerable efficacy in the treatment of non-resectable feline cutaneous squamous cell carcinoma (cSCC), boasting response rates of up to 95%, but other chemotherapy protocols have not yet been investigated. The objective of this prospective multicentre study was to compare the overall response rate (ORR) and progression-free interval (PFI) between cats with cSCC treated with ECT using IT and IV carboplatin (IV + IT), IV carboplatin (IV) or IV bleomycin (IV). A total of 44 cats with unresectable cSCC across three centres were enrolled and treated with ECT using carboplatin IV + IT (n = 10), carboplatin IV (n = 11) or bleomycin IV (n = 23). Treatment response according to RECIST criteria was recorded at 2 and 4 weeks post-treatment, and patients were followed until disease progression and/or death. All three groups were comparable regarding age, sex, weight, and lesion size. Adverse events were generally mild, localised and similar between groups. ORRs were 90.0% (carboplatin IV + IT), 90.9% (carboplatin IV) and 95.6% (bleomycin IV) and were not significantly different (p = 0.79). Median PFI was not reached for carboplatin IV + IT or carboplatin IV and was 566 days for bleomycin IV, with no significant difference between the three groups (p = 0.81). This study suggests that ECT using IV or IV + IT carboplatin is a reasonable alternative therapeutic option for managing cSCC, and further studies are warranted to compare outcomes between treatment protocols.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"437-446"},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterization of the dissemination of canine cancer misinformation on YouTube. YouTube 上传播犬类癌症错误信息的特点。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2024-09-01 Epub Date: 2024-04-28 DOI: 10.1111/vco.12977

Eliza R Richartz, Brittany A Hodgkiss, Noah C Black-Ocken, Rebecca A Fuentes, Jayme S Looper, Sita S Withers

{"title":"Characterization of the dissemination of canine cancer misinformation on YouTube.","authors":"Eliza R Richartz, Brittany A Hodgkiss, Noah C Black-Ocken, Rebecca A Fuentes, Jayme S Looper, Sita S Withers","doi":"10.1111/vco.12977","DOIUrl":"10.1111/vco.12977","url":null,"abstract":"YouTube is the third most popular app in the world and continues to grow each year while it reaches over 2 billion users a month. A variety of veterinary topics are addressed on YouTube but to date there have been no studies analysing misinformation of various canine cancer topics on YouTube or social media. This study described the characteristics of 99 unique videos and used the validated DISCERN quality criteria for consumer health information and the Patient Education Materials Assessment Tool (PEMAT) to characterize their usefulness. The overall median DISCERN quality score was 3 (out of 5), the median PEMAT understandability score was 72%, and 61% of videos contained little to no misinformation. 53% of videos were created by veterinarians and this subset had significantly higher PEMAT understandability and DISCERN quality scores compared with client-created content (p = .0228 and p ≤ .0001, respectively). Videos with little to no misinformation had statistically significant higher DISCERN quality scores (3 vs. 2, p = .0001). There was no statistical significance between misinformation levels and video length, PEMAT understandability, thumbs up/view, or views/mo. These data reveal similar rates of misinformation in videos on canine cancer compared to that reported for various human cancer topics. This study highlights the need for veterinarians to guide clients to more reliable and understandable information regarding their pet's health.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"359-366"},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of Stereotactic Radiation Therapy Versus Fractionated Radiation Therapy in 44 Dogs With Pituitary Masses: A Multi-Institutional Retrospective Study (2016-2022). 立体定向放射治疗与分次放射治疗在 44 只垂体肿块犬中的疗效：一项多机构回顾性研究（2016-2022年）》。

IF 2.3 2区农林科学

Veterinary and comparative oncology Pub Date : 2024-09-01 Epub Date: 2024-06-18 DOI: 10.1111/vco.12991

Tracy L Gieger, Leanne Magestro, Jillian Walz, Hiroto Yoshikawa, Michael W Nolan

{"title":"Outcomes of Stereotactic Radiation Therapy Versus Fractionated Radiation Therapy in 44 Dogs With Pituitary Masses: A Multi-Institutional Retrospective Study (2016-2022).","authors":"Tracy L Gieger, Leanne Magestro, Jillian Walz, Hiroto Yoshikawa, Michael W Nolan","doi":"10.1111/vco.12991","DOIUrl":"10.1111/vco.12991","url":null,"abstract":"Although canine pituitary masses (PM) are increasingly treated with stereotactic radiotherapy (SRT), historical literature supports superior outcomes with conventional full-course fractionated radiation therapy (FRT). A multi-institutional retrospective study was performed, including dogs with PM treated from 2016 to 2022 with SRT (total dose 30 or 35 Gy in 5 daily fractions) or FRT (total dose 50-54 Gy in 19-20 daily fractions). The influence of potential prognostic/predictive factors was assessed, including pituitary: brain height, pituitary: brain volume, sex, age and endocrine status (functional [F] vs. nonfunctional [NF] PM). Forty-four dogs with PM were included (26 F, 14 NF, 4 unknown). All patients completed protocols as scheduled (SRT = 27, FRT = 17) and two dogs had suspected Grade 1 acute neurotoxicity. During the first 6 months after RT, 5/27 (19%) dogs treated with SRT (4 F, 1 NF) and 3/17 (18%) dogs treated with FRT (all F) died or were euthanised because of progressive neurologic signs. The overall median survival time was 608 days (95% CI, 375-840 days). Young age at the time of treatment was significant for survival (p = 0.0288); the overall median survival time was 753 days for dogs <9 years of age (95% CI, 614-892 days) and 445 days for dogs ≥9 years of age (95% CI, 183-707 days). Survival time was not associated with treatment type or any other factor assessed herein. A prospective study using standardised protocols would further validate the results of the present study and potentially elucidate the predictors of early death.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"429-436"},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasma cell-free DNA in canine lymphoma patients as a novel material for genotyping. 犬淋巴瘤患者血浆中的无细胞 DNA 可作为基因分型的新型材料。

IF 2.1 2区农林科学

Veterinary and comparative oncology Pub Date : 2024-06-01 Epub Date: 2024-01-29 DOI: 10.1111/vco.12961

Satoshi Kambayashi, Nanae Ono, Tomofumi Tone, Kenji Baba, Masaru Okuda

{"title":"Plasma cell-free DNA in canine lymphoma patients as a novel material for genotyping.","authors":"Satoshi Kambayashi, Nanae Ono, Tomofumi Tone, Kenji Baba, Masaru Okuda","doi":"10.1111/vco.12961","DOIUrl":"10.1111/vco.12961","url":null,"abstract":"Canine lymphoma is a disease with high morbidity and poor long-term prognosis, despite a high response rate to chemotherapy. In this study, we focused on liquid biopsy, in which small amounts of substances from body fluids were analysed, to determine whether cell-free DNA (cfDNA) in the plasma can be used as a biomarker for lymphoma in dogs. We found that 23 patients with lymphoma had significantly higher cfDNA concentrations than the 12 healthy dogs (median 2360 ng/mL versus 299 ng/mL, p < .0001). Polymerase chain reaction for antigen receptor rearrangement (PARR) was also employed using cfDNA from the lymphoma group to investigate whether cfDNA could be used for the detection of genetic clonality of lymphomas, as well as the genomic DNA (gDNA) extracted from an original lesion in each case. The correlation of the PARR results between cfDNA and gDNA was observed in 100% of B-cell lymphomas (10/10), 77.8% of T-cell lymphomas (7/9), and 100% of other types of lymphomas (4/4), respectively. These results indicate that plasma cfDNA levels are increasing in canine lymphoma patients, that cfDNA concentration can be a novel diagnostic tool, and that it can be used as a diagnostic tool for PARR.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"303-309"},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sodium iodide symporter immunolabelling as a predictor of clinical iodide uptake in canine thyroid carcinoma: A preliminary study. 碘化钠交感蛋白免疫标记作为犬甲状腺癌临床碘摄取的预测指标：一项初步研究。

IF 2.1 2区农林科学

Veterinary and comparative oncology Pub Date : 2024-06-01 Epub Date: 2024-03-15 DOI: 10.1111/vco.12971

Katelin V Dark, Owen T Skinner, Dae Young Kim, James J Karnia, Megan A Mickelson, Charles A Maitz

{"title":"Sodium iodide symporter immunolabelling as a predictor of clinical iodide uptake in canine thyroid carcinoma: A preliminary study.","authors":"Katelin V Dark, Owen T Skinner, Dae Young Kim, James J Karnia, Megan A Mickelson, Charles A Maitz","doi":"10.1111/vco.12971","DOIUrl":"10.1111/vco.12971","url":null,"abstract":"Thyroid follicular tumours may take up iodide via the sodium-iodide symporter. Knowledge of iodide uptake could then allow treatment with I-131 in dogs with high-risk tumours. The objective of this study was to determine the relationship between clinically detectable iodide uptake (as determined by scintigraphy and/or thyroxine concentrations) and sodium iodide symporter immunohistochemical labelling on histologically fixed thyroid tumours. Nineteen dogs were identified who were diagnosed with thyroid carcinoma and underwent surgery from November 2017 to July 2021. All had recorded thyroid hormone concentrations and were hyperthyroid and/or underwent preoperative nuclear imaging using planar scintigraphy (technetium-99m or I-123), or I-124 PET-CT. All dogs subsequently underwent surgery to remove the thyroid mass. Twenty-two tumours were submitted for histopathologic analysis immediately following surgery, which confirmed a diagnosis of thyroid carcinoma for each tumour. Images and/or thyroid hormone concentrations were reviewed for the included cases, and tumours were sorted into an avid/functional group (group 1) and a non-avid/functional group (group 2). The tumour tissues were re-examined histologically using sodium iodide symporter (NIS) immunohistochemistry (IHC). Group 1 contained 15 avid/functional tumours. Twelve of these tumours had membranous NIS IHC labelling. Group 2 contained 7 non-avid tumours. One of these tumours had membranous NIS IHC labelling. This resulted in an overall sensitivity and specificity for identification of avid/functional tumours with membranous NIS of 80.0% and 85.7%, respectively. NIS IHC may predict ion trapping in canine follicular thyroid tumours. Further studies using iodide-based imaging are warranted to better determine the clinical utility of this diagnostic modality.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"239-244"},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140132709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo. trastuzumab emtansine 对犬尿路上皮癌细胞在体外和体内的影响。

IF 2.1 2区农林科学

Veterinary and comparative oncology Pub Date : 2024-06-01 Epub Date: 2024-03-19 DOI: 10.1111/vco.12970

Kosei Sakai, Daiki Kato, Junka Yoshinaka, Yosuke Takahashi, Namiko Ikeda, Susumu Aoki, Takaaki Iguchi, Shingo Ishikawa, Norio Yamagishi, Shunsuke Shimamura, Takayuki Nakagawa

{"title":"Effects of trastuzumab emtansine on canine urothelial carcinoma cells in vitro and in vivo.","authors":"Kosei Sakai, Daiki Kato, Junka Yoshinaka, Yosuke Takahashi, Namiko Ikeda, Susumu Aoki, Takaaki Iguchi, Shingo Ishikawa, Norio Yamagishi, Shunsuke Shimamura, Takayuki Nakagawa","doi":"10.1111/vco.12970","DOIUrl":"10.1111/vco.12970","url":null,"abstract":"Urothelial carcinoma (UC) is the most common malignancy of the urinary tract in dogs and has aggressive behaviour. Although human epidermal growth factor receptor 2 (HER2) is a known therapeutic target with evidence in canine UC, the efficacy of anti-HER2 antibody drugs remains unknown. This study aimed to investigate the effects of anti-HER2 antibody drugs including trastuzumab and trastuzumab emtansine (T-DM1) on canine UC cell lines in vitro and in vivo. Four canine UC cell lines (Nene, TCCUB, Love, and Sora) were used. In western blotting, HER2 protein expression was observed in all the cell lines. Although both trastuzumab and T-DM1 showed dose-dependent growth inhibitory activity in the cell lines, T-DM1 showed much stronger activity than that of trastuzumab. In flow cytometry analyses with the canine UC cell line (Sora), T-DM1 but not trastuzumab significantly increased the percentages of early and late apoptotic cells in annexin V apoptotic assays and the sub-G1 phase fraction in cell cycle analyses. For the in vivo experiment, the canine UC cells (Sora) were subcutaneously injected into nude mice. Four days after inoculation, trastuzumab, T-DM1, or vehicle was administered intraperitoneally once a week for three times. Tumour volumes were significantly smaller in the T-DM1 group compared to the trastuzumab and vehicle control groups. These findings indicate that T-DM1 exerts a stronger antitumour effect than that of trastuzumab on canine UC cells in vitro and in vivo, possibly by inducing apoptosis due to DM1.","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"230-238"},"PeriodicalIF":2.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140176759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0